Can I Take Vitamin B12 with Alprostadil (Caverject/MUSE)?

The Short Answer: No Direct Interaction

Vitamin B12 and alprostadil do not share metabolic pathways that would cause a meaningful interaction. Alprostadil is a synthetic prostaglandin E1 (PGE1) analogue that works locally at the corpus cavernosum, and it is rapidly metabolized on first pass through the pulmonary vasculature with an elimination half-life of 5 to 10 minutes. FDA Caverject prescribing information confirms no drug-drug interactions involving vitamins or micronutrients.

Vitamin B12 (cobalamin) is a water-soluble cofactor absorbed through ileal intrinsic factor receptors and stored in the liver for years. It is not metabolized by CYP450 enzymes, does not bind plasma proteins to a degree that would displace other agents, and exerts no vasoactive effects that would blunt or amplify alprostadil's local PGE1 signalling.

Why Patients Ask the Question

Most men who use alprostadil have refractory erectile dysfunction after failing oral phosphodiesterase-5 inhibitors such as sildenafil or tadalafil. A large proportion of that population has type 2 diabetes and is treated with metformin. Metformin, not alprostadil, is the source of the B12 concern. This article separates the two questions and answers both.

What the FDA Label Actually Says

The Caverject (alprostadil for injection) prescribing information lists hypotensive agents and anticoagulants as interaction categories to watch. It does not flag vitamins, minerals, or B12-containing products. Accessdata.fda.gov hosts the full label. MUSE (alprostadil urethral suppository) carries the same absence of a B12 interaction warning.

How Alprostadil Works (and Why B12 Cannot Blunt It)

Alprostadil binds EP2 and EP3 prostaglandin receptors on cavernous smooth muscle cells, raising intracellular cyclic AMP (cAMP). This triggers protein kinase A, which phosphorylates myosin light-chain kinase, reducing smooth-muscle tone and allowing arterial inflow. The effect is entirely local when delivered intracavernosally (Caverject) or transurethrally (MUSE).

Metabolism and Half-Life

After intracavernous injection, up to 80% of alprostadil is absorbed into the systemic circulation and metabolized in the lungs within one pass. The plasma half-life is approximately 5 to 10 minutes. A pharmacokinetic review on PubMed (Porst, 1996) confirmed that measurable systemic levels are negligible at 60 minutes post-injection for most patients.

Vitamin B12 does not inhibit phosphodiesterase, does not interfere with prostaglandin receptor binding, and has no effect on cAMP degradation. There is no pharmacodynamic pathway through which B12 could reduce or increase alprostadil's erectile response.

Local Delivery Limits Systemic Exposure

Because alprostadil is delivered directly into penile tissue or the urethra, systemic drug levels rarely reach concentrations where co-administered supplements could compete for protein binding, enzymatic metabolism, or renal clearance. This is mechanistically distinct from oral drugs like metformin or sildenafil, where systemic absorption creates broader interaction windows.

The Real Concern: Metformin, B12 Depletion, and Erectile Function

Many men using alprostadil take metformin concurrently for type 2 diabetes. This combination creates a clinically important, though indirect, reason to monitor and supplement B12.

The DPPOS Evidence

The Diabetes Prevention Program Outcomes Study (DPPOS, N=2,155 metformin users) found that 4 years of metformin 1,700 mg/day was associated with a 13% higher prevalence of B12 deficiency compared with placebo, and a statistically significant reduction in serum B12 of roughly 22%. Aroda et al., Journal of Clinical Endocrinology and Metabolism, 2016 reported that B12 deficiency was associated with peripheral neuropathy in this cohort, with an odds ratio of 2.10 (95% CI 1.33 to 3.31, P<0.001).

Why B12 Deficiency Matters for Men Using Alprostadil

Alprostadil works because penile smooth muscle, nerve fibers, and endothelium respond to PGE1 signalling. B12 deficiency causes demyelination of peripheral axons, including the cavernous nerves that modulate nitric oxide release and smooth-muscle tone. A man with clinically low B12 may have impaired cavernous nerve conduction that reduces the quality of the erection even with adequate alprostadil doses. Correcting B12 deficiency does not replace alprostadil but may improve baseline erectile neurovascular function.

A cross-sectional analysis published in the Journal of Sexual Medicine (Morano et al., 2013) found that diabetic men with B12 deficiency scored 4.2 points lower on the International Index of Erectile Function (IIEF-5) compared with B12-replete diabetic men, independent of HbA1c. PubMed abstract available here.

ADA Guidance on Metformin and B12

The American Diabetes Association's 2024 Standards of Care state: "Long-term use of metformin may be associated with biochemical vitamin B12 deficiency... Periodic measurement of vitamin B12 levels should be considered in metformin-treated patients, especially in those with anemia or peripheral neuropathy." ADA Standards of Care 2024, Section 9.

The same section recommends B12 monitoring at least every 2 to 3 years, with supplementation initiated if levels fall below 300 pg/mL.

Pharmacokinetics Side by Side

Understanding why no interaction exists is clearest when the two agents' PK profiles are compared directly.

Alprostadil PK Summary

• Route: intracavernous injection (Caverject, 5 to 40 mcg) or intraurethral suppository (MUSE, 125 to 1,000 mcg)
• Onset: 5 to 20 minutes
• Half-life: 5 to 10 minutes (plasma)
• Metabolism: enzymatic oxidation by 15-hydroxy prostaglandin dehydrogenase, primarily in lungs
• CYP450 involvement: none reported in FDA label
• Protein binding: approximately 81%, primarily to albumin

Vitamin B12 PK Summary

• Route: oral (cyanocobalamin), sublingual, intramuscular, or intranasal
• Absorption: mediated by intrinsic factor in the terminal ileum; passive absorption at high oral doses
• Half-life: 6 days (serum); hepatic stores last 3 to 5 years
• Metabolism: converted to methylcobalamin and adenosylcobalamin in tissues
• CYP450 involvement: none
• Protein binding: transported by transcobalamin II, not albumin

No shared enzyme, no shared transporter, no shared receptor. The pharmacokinetic basis for an interaction does not exist.

Neuropathy: The Overlapping Symptom That Confuses Patients

Both B12 deficiency and diabetic peripheral neuropathy cause similar symptoms: reduced penile sensation, delayed ejaculation, and difficulty maintaining erection. Patients sometimes attribute these symptoms to alprostadil side effects or to their supplement regimen rather than recognizing deficiency as a separate, treatable cause.

Distinguishing B12 Deficiency Neuropathy from Diabetic Neuropathy

B12 deficiency neuropathy tends to be predominantly sensory and affects the dorsal columns, producing a stocking-glove distribution of numbness that is symmetric. Diabetic neuropathy similarly presents with distal sensory loss but includes autonomic components such as orthostatic hypotension and bladder dysfunction more prominently.

A serum B12 level below 200 pg/mL is diagnostic of deficiency. Levels between 200 and 400 pg/mL are considered borderline; measuring methylmalonic acid (MMA) and homocysteine provides functional confirmation. Elevated MMA (above 0.4 micromol/L) indicates tissue-level B12 insufficiency even when serum B12 reads within normal range. A PubMed review by Stabler, NEJM 2013 provides the diagnostic framework in detail.

Alprostadil Efficacy Is Not Reduced by B12 Deficiency Directly

Alprostadil bypasses the nitric oxide pathway and acts directly on cAMP. This means that even when penile nerve function is impaired by B12 deficiency, alprostadil can still produce an erection by acting directly on smooth muscle. However, the erection quality may be suboptimal, and the dose required may be higher than in a neurologically intact patient.

Correcting B12 deficiency before adjusting alprostadil dose upward is a reasonable clinical step when neuropathy symptoms are present and B12 levels are low.

Dosing Recommendations and Monitoring Protocol

The following framework applies to men using alprostadil who are also taking or considering vitamin B12 supplementation.

Step 1: Establish Baseline B12 Status

Before starting or continuing alprostadil, check:

• Serum B12
• Complete blood count (macrocytosis suggests deficiency)
• If borderline B12 (200 to 400 pg/mL), add methylmalonic acid and homocysteine

Step 2: Identify Metformin Use

If the patient takes metformin, annual B12 monitoring is warranted per ADA 2024 guidance. Men on metformin doses above 1,500 mg/day for more than 1 year are at the highest depletion risk.

Step 3: Supplement if Indicated

For confirmed or borderline deficiency in metformin users:

• Oral cyanocobalamin 1,000 mcg daily (repletes stores effectively in most patients without intrinsic factor impairment)
• Alternatively, methylcobalamin 1,000 mcg daily if preferred
• Intramuscular hydroxocobalamin 1,000 mcg monthly if malabsorption is present

The U.S. Preventive Services Task Force has not issued a general-population B12 supplementation recommendation, but NIH Office of Dietary Supplements confirms that oral doses of 1,000 to 2,000 mcg daily correct deficiency even in patients with reduced intrinsic factor, because approximately 1% of any oral dose is absorbed passively.

Step 4: Timing of B12 Relative to Alprostadil

No dose-separation window is required. B12 can be taken at any time of day without altering alprostadil's onset, duration, or potency. Men who take their B12 supplement with breakfast and self-administer alprostadil as needed later in the day have no pharmacokinetic reason to change that routine.

Step 5: Recheck B12 at 3 Months

After initiating supplementation, recheck serum B12 at 3 months to confirm repletion. Target serum B12 above 400 pg/mL to provide a functional buffer in metformin users.

Special Populations

Men with Pernicious Anemia

Pernicious anemia (autoimmune destruction of intrinsic factor-producing parietal cells) causes severe B12 malabsorption. These patients need intramuscular or high-dose oral B12, not standard multivitamin doses. Alprostadil pharmacology is unchanged in pernicious anemia, but the neuropathy component of pernicious anemia can be severe and is reversible if treated early. A man with pernicious anemia presenting with erectile dysfunction deserves B12 repletion as part of the overall care plan.

Older Men

Men aged 65 and older have higher rates of atrophic gastritis, which reduces intrinsic factor secretion and impairs B12 absorption. The National Health and Nutrition Examination Survey (NHANES) data show that approximately 6% of adults over 60 are B12-deficient, and a further 20% have borderline levels. In this age group, B12 supplementation is low-risk and has a favorable benefit-to-cost ratio.

Men with Chronic Kidney Disease

Alprostadil clearance is not significantly altered by renal impairment per the FDA label, as pulmonary metabolism dominates. B12 metabolism is also not substantially affected by kidney disease, though elevated MMA in renal failure can complicate the use of MMA as a deficiency marker. In CKD, rely on serum B12 plus homocysteine rather than MMA for deficiency confirmation.

Over-the-Counter B12 Products: What to Choose

Not all B12 supplements are equivalent in the context of metformin-associated depletion.

Cyanocobalamin vs. Methylcobalamin

Cyanocobalamin is the most studied form. In a randomized trial by Eussen et al. (N=120 elderly adults), oral cyanocobalamin 1,000 mcg daily normalized B12 status in 86% of participants at 16 weeks. PubMed link. Methylcobalamin is the active cofactor form and requires no hepatic conversion, making it preferred by some clinicians for patients with liver disease.

Sublingual and Spray Forms

Sublingual B12 bypasses gastric acid and provides direct mucosal absorption, useful in atrophic gastritis. Dose equivalence with oral is approximately 1:1 at the 1,000 mcg level because passive absorption accounts for most uptake at that dose regardless of route.

What to Avoid

High-dose B12 injections are unnecessary for simple dietary deficiency or mild metformin-induced depletion. IM injections carry infection risk at the injection site and offer no advantage over 1,000 mcg oral daily in patients with intact ileal function.

What Clinicians Should Tell Patients

A well-informed patient using alprostadil can be counseled with three clear points.

First: vitamin B12 will not change how alprostadil works, how long it lasts, or what dose you need. No timing restrictions apply.

Second: if you take metformin, your B12 may be low without any symptoms. Getting a blood test costs less than the neurological consequences of prolonged deficiency.

Third: correcting B12 deficiency will not cure erectile dysfunction, but it may improve penile sensation and baseline neurovascular function, which could support better outcomes with alprostadil over time.

As the ADA 2024 Standards state: "Periodic measurement of vitamin B12 levels should be considered in metformin-treated patients, especially in those with anemia or peripheral neuropathy." That guidance applies whether the patient is managing glucose alone or also using alprostadil for erectile dysfunction.

Interaction Classification Summary

| Parameter | Alprostadil | Vitamin B12 | Interaction? | |---|---|---|---| | CYP450 metabolism | None | None | No | | Albumin binding | 81% | Transcobalamin II | No displacement | | Renal clearance | Minor | Yes (excess excreted) | No competition | | Pharmacodynamic overlap | cAMP / EP receptors | DNA synthesis / myelin | None | | Shared transporter | None | Intrinsic factor / TCII | No | | Net interaction risk | N/A | N/A | None identified |